The U.S. Food and Drug Administration's mission includes both the advancement of public health by helping to speed innovation and the assurance of the safety and efficacy of new and innovative products.  However, the current balance struck at the FDA has curtailed innovation and, if not rectified, will negatively affect the availability of innovative medical products in the future.  

Hear what Heron Capital's Managing Director, Greg Maurer, has to say about uncertainty at the FDA.

Watch the Business of Health segment